SAN DIEGO--(BUSINESS WIRE)--Cytori (NASDAQ:CYTX) announced today it has been informed that seven new investigator-initiated clinical studies in Japan using adipose-derived regenerative cells have been approved by local ethical committees. The approvals are at leading academic university hospitals and include a diverse group of therapeutic applications.
